相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
May Daher et al.
BLOOD (2021)
Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO
Chantiya Chanswangphuwana et al.
MOLECULAR THERAPY (2021)
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
Tatiana Pazina et al.
CANCERS (2021)
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Urvi A. Shah et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
The role of AhR in transcriptional regulation of immune cell development and function
Prashant Trikha et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Checkpoint inhibitors in AML: are we there yet?
Arnab Ghosh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma
H. J. Close et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity
Jing Ni et al.
IMMUNITY (2020)
Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?
Pilar M. Lanuza et al.
FRONTIERS IN IMMUNOLOGY (2020)
CD56bright/CD16bright NK-cell adoptive immunotherapy in patients with concurrent CNS disease and relapsed or refractory (R/R) AML.
Lucia Silla et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
Xiangli Chen et al.
MEDICINE (2020)
Overcoming hypoxia-induced functional suppression of NK cells
Kristen Solocinski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
Kristiina Karihtala et al.
CANCERS (2020)
Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience
Mee-seon Kim et al.
DIAGNOSTICS (2020)
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity
Meisam Naeimi Kararoudi et al.
BLOOD (2020)
T follicular helper cell-mediated IL-21 production suppresses FOXP3 expression of T follicular regulatory-like cells in diffuse large B cell lymphoma patients
Xiaomei Ma et al.
HUMAN IMMUNOLOGY (2020)
Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager
Martin Felices et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Xiaomei Wang et al.
BLOOD ADVANCES (2020)
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
Marie-Helene Delfau-Larue et al.
BLOOD ADVANCES (2020)
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
Wendy B. C. Stevens et al.
HEMASPHERE (2020)
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The role of TGFβ in hematopoiesis and myeloid disorders
Alex Bataller et al.
LEUKEMIA (2019)
PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data
Young Wha Koh et al.
LUNG CANCER (2019)
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL
Florian Babor et al.
BONE MARROW TRANSPLANTATION (2019)
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study
Torben Plesner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Rachel A. Burga et al.
CLINICAL CANCER RESEARCH (2019)
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
Jan Philipp Bewersdorf et al.
LEUKEMIA (2019)
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
Fotini Vogiatzi et al.
BLOOD (2019)
Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
Dean A. Lee
IMMUNOLOGICAL REVIEWS (2019)
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
Kristina Ellwanger et al.
MABS (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells
Anish K. Ray et al.
PEDIATRIC BLOOD & CANCER (2019)
Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
Jian Chen et al.
TRENDS IN MOLECULAR MEDICINE (2019)
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong et al.
CANCER DISCOVERY (2019)
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Selena Vigano et al.
FRONTIERS IN IMMUNOLOGY (2019)
TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression
Chin-Han Huang et al.
IMMUNOBIOLOGY (2019)
Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
Evelyn O. Ojo et al.
SCIENTIFIC REPORTS (2019)
Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control
Bartosz Grzywacz et al.
JOURNAL OF IMMUNOTHERAPY (2019)
A Novel Liposomal S-Propargyl-Cysteine: A Sustained Release of Hydrogen Sulfide Reducing Myocardial Fibrosis via TGF-β1/Smad Pathway
Ba Hieu Tran et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
Michelle L. Saetersmoen et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation
Annekathrin Heinze et al.
FRONTIERS IN IMMUNOLOGY (2019)
Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector
Aurelien B. L. Colamartino et al.
FRONTIERS IN IMMUNOLOGY (2019)
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Sarah Cooley et al.
BLOOD ADVANCES (2019)
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
Moshe Yeshurun et al.
BLOOD ADVANCES (2019)
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
Martin Felices et al.
BLOOD ADVANCES (2019)
Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors
Andrea M. Chambers et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2019)
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Karen L. Bride et al.
BLOOD (2018)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells
Yufeng Wang et al.
CLINICAL CANCER RESEARCH (2018)
Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy
Hui Ding et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors
Laurent-Olivier Roy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
PD-1 blocks lytic granule polarization with concomitant impairment of integrin outside-in signaling in the natural killer cell immunological synapse
Yu Huang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways
Yuanyuan Zhao et al.
MOLECULAR ONCOLOGY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Contextual determinants of TGFβ action in development, immunity and cancer
Charles J. David et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives
Stanislaw Schmidt et al.
Oncotarget (2018)
Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins
Meisam Naeimi Kararoudi et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2018)
Acquired natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma
Jodi Chiu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function
Steven D. Scoville et al.
BLOOD (2018)
Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade
Simone A. Minnie et al.
BLOOD (2018)
Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells
Gloria Pelizzo et al.
BMC CANCER (2018)
Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Jiao Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Kathleen E. Fenerty et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion
Jennifer A. Foltz et al.
CANCERS (2018)
Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells
Veronika Bachanova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Arabella Young et al.
CANCER RESEARCH (2018)
Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype
Nargess Arandi et al.
BLOOD RESEARCH (2018)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
The prognostic importance of TGF-, TGF- receptor, and fascin in childhood solid tumors
Hikmet Gulsah Tanyildiz et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2017)
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary B. Davis et al.
SEMINARS IN IMMUNOLOGY (2017)
Targeting TGF-β Signaling for Therapeutic Gain
Rosemary J. Akhurst
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2017)
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams et al.
ONCOTARGET (2017)
Prognostic implication of leucocyte subpopulations in diffuse large B-cell lymphoma
Xiao Han et al.
ONCOTARGET (2017)
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
Massimo Giuliani et al.
ONCOTARGET (2017)
Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells
Fatemeh Vahedi et al.
SCIENTIFIC REPORTS (2017)
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
Anne-Sophie Chretien et al.
FRONTIERS IN IMMUNOLOGY (2017)
Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors
Eva M. Palsson-McDermott et al.
FRONTIERS IN IMMUNOLOGY (2017)
Tumor-priming converts NK cells to memory-like NK cells
Marina Pal et al.
ONCOIMMUNOLOGY (2017)
The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
Isabel Goncalves Silva et al.
EBIOMEDICINE (2017)
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Hannah A. Blair
DRUGS (2017)
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Karen Thudium Mueller et al.
BLOOD (2017)
Phase 1 clinical trial of adoptive immunotherapy using off-the-shelf activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Michael Boyiadzis et al.
CYTOTHERAPY (2017)
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
Stefan O. Ciurea et al.
BLOOD (2017)
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma
Eric S. Yvon et al.
CYTOTHERAPY (2017)
The breast tumor microenvironment alters the phenotype and function of natural killer cells
Tamara Krneta et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2016)
The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia
R. H. Rouce et al.
LEUKEMIA (2016)
Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation
Veronika Bachanova et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Mattias Carlsten et al.
CLINICAL CANCER RESEARCH (2016)
Natural Killer Cells for immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells
Hans Klingemann et al.
FRONTIERS IN IMMUNOLOGY (2016)
Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing
Conor J. Kearney et al.
ONCOIMMUNOLOGY (2016)
Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia
Muhammad Zaeem Noman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2015)
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Kathryn Lagrue et al.
BLOOD (2015)
A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
Yoshikane Kikushige et al.
CELL STEM CELL (2015)
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Liyun Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21
Xiaomei Li et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion
Zena Khaznadar et al.
JOURNAL OF IMMUNOLOGY (2015)
Human Cytokine-Induced Memory-Like Natural Killer Cells
Melissa M. Berrien-Elliott et al.
JOURNAL OF INNATE IMMUNITY (2015)
Increased NK cell maturation in patients with acute myeloid leukemia
Anne-Sophie Chretien et al.
FRONTIERS IN IMMUNOLOGY (2015)
Transforming growth factor-beta and its implication in the malignancy of gliomas
Laurent-Olivier Roy et al.
TARGETED ONCOLOGY (2015)
Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Yaya Chu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Autophagic degradation of GZMB/granzyme B
Elodie Viry et al.
AUTOPHAGY (2014)
Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy
Jeffrey S. Miller et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL
Lena Oevermann et al.
BLOOD (2014)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study
Ji-Young Choe et al.
BMC CANCER (2014)
Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21
Bo Jiang et al.
CELLULAR IMMUNOLOGY (2014)
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
Kate Stringaris et al.
HAEMATOLOGICA (2014)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia
Sarah Cooley et al.
JOURNAL OF IMMUNOLOGY (2014)
The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies
Barbara Muz et al.
MOLECULAR CANCER RESEARCH (2014)
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells
Sarah S. Donatelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Ines Pires da Silva et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Reversal of natural killer cell exhaustion by TIM-3 blockade
Anne Gallois et al.
ONCOIMMUNOLOGY (2014)
Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers
M. Stern et al.
BONE MARROW TRANSPLANTATION (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC
Mirna Balsamo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
P. Glorius et al.
LEUKEMIA (2013)
GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer Cells In Vitro and In Vivo
Okjae Lim et al.
PLOS ONE (2013)
Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice
Jeannette Cany et al.
PLOS ONE (2013)
Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells
Subhashis Sarkar et al.
PLOS ONE (2013)
Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
Nina Shah et al.
PLOS ONE (2013)
Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
David A. Knorr et al.
STEM CELLS TRANSLATIONAL MEDICINE (2013)
Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
Laurent Boissel et al.
ONCOIMMUNOLOGY (2013)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
Cytokine activation induces human memory-like NK cells
Rizwan Romee et al.
BLOOD (2012)
Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients
Beatriz Sanchez-Correa et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors
Jing Ni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity
C. Kellner et al.
LEUKEMIA (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Application of IL-2 therapy to target T regulatory cell function
Ethan M. Shevach
TRENDS IN IMMUNOLOGY (2012)
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
Soranobu Ninomiya et al.
ANNALS OF HEMATOLOGY (2011)
Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1
Yuk Pheel Park et al.
BLOOD (2011)
Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
Christian Kellner et al.
CANCER LETTERS (2011)
Hypoxia Induces Escape from Innate Immunity in Cancer Cells via Increased Expression of ADAM10: Role of Nitric Oxide
Ivraym B. Barsoum et al.
CANCER RESEARCH (2011)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
Pier Luigi Zinzani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Transforming Growth Factor-β in the Gastrointestinal and Hepatic Tumor Microenvironment
Bhagelu Ram Achyut et al.
GASTROENTEROLOGY (2011)
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
Ingo Schubert et al.
MABS (2011)
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Jan Spanholtz et al.
PLOS ONE (2011)
Cytokine regulation of natural killer cell effector functions
Norberto W. Zwirner et al.
BIOFACTORS (2010)
Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation
David A. Rizzieri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation
Heather J. Symons et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
Sarah Cooley et al.
BLOOD (2010)
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects
Janelle A. Olson et al.
BLOOD (2010)
Allogeneic natural killer cells for refractory lymphoma
Veronika Bachanova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
Petter S. Woll et al.
BLOOD (2009)
Replicative potential of human natural killer cells
Hiroyuki Fujisaki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki et al.
CANCER RESEARCH (2009)
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
Maria Berg et al.
CYTOTHERAPY (2009)
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
Laurent Boissel et al.
LEUKEMIA RESEARCH (2009)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Noa Stanietsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation
Sandrine Meyer-Monard et al.
TRANSFUSION (2009)
Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells
Laurent Boissel et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
Jumei Shi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia
Xiangli Chen et al.
CANCER BIOLOGY & THERAPY (2008)
Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: Role of nitric oxide
D. Robert Siemens et al.
CANCER RESEARCH (2008)
TGF-β utilizes SMAD3 to inhibit CD16-mediated IFN-γ production and antibody-dependent cellular cytotoxicity in human NK cells
Rossana Trotta et al.
JOURNAL OF IMMUNOLOGY (2008)
Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
B. N. Savani et al.
LEUKEMIA (2007)
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism
Evdoxia Hatjiharissi et al.
BLOOD (2007)
TGFβ promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells
Derin B. Keskin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase
A. Curti et al.
LEUKEMIA (2007)
In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection
Yan Zhang et al.
IMMUNOLOGY (2007)
Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering
Janet Ayello et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
M Ahmadzadeh et al.
BLOOD (2006)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes
JJ Kiladjian et al.
LEUKEMIA (2006)
Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors
DH Kim et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Natural killer cell alloreactivity for leukemia therapy
L Ruggeri et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
P Nowbakht et al.
BLOOD (2005)
Characterization of cord blood natural killer cells:: Implications for transplantation and neonatal infections
JH Dalle et al.
PEDIATRIC RESEARCH (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells
J Bruenke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Loss of Smad3 in acute T-cell lymphoblastic leukemia
LA Wolfraim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells
H Harada et al.
EXPERIMENTAL HEMATOLOGY (2004)
Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients
JC Lee et al.
JOURNAL OF IMMUNOLOGY (2004)
Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation
JR Passweg et al.
LEUKEMIA (2004)
Ex vivo expansion of natural killer cells for clinical applications
HG Klingemann et al.
CYTOTHERAPY (2004)
Purification of human natural killer cells using a clinical-scale immunomagnetic method
R Iyengar et al.
CYTOTHERAPY (2003)
Natural killer cell-mediated basal and interferon-enhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions
T Fink et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2003)
Influence of transplanted dose of CD56+cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors
S Yamasaki et al.
BONE MARROW TRANSPLANTATION (2003)
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors
S Giebel et al.
BLOOD (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells
MA Cooper et al.
BLOOD (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
分享论文
